In the News
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher Disease
09 December 2010
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease CARMIEL, Israel--(BUSINESS WIRE)--Protalix Biotherapeu...
Read more....
-
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
29 November 2010
New York, NY/Carmiel, Israel, November 29, 2010 – Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX)today announced...
Read more....
-
Head-to-Head Data Demonstrates Efficacy of VPRIVA
08 November 2010
Cambridge, MA, US – November 4, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented positive n...
Read more....
-
Positive Data from taliglucerase alfa Switchover Trial
08 November 2010
Protalix BioTherapeutics, Inc. announced positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, mult...
Read more....
-
9th EWGGD Proceedings
20 October 2010
Publication of the Proceedings of the 9th European Working Group on Gaucher Disease (EWGGD) The European Gaucher Alliance (EGA) has published the p...
Read more....
-
European Commission Approval of VPRIV ( velaglucerase alfa)
28 August 2010
Cambridge, MA, US – 26th August 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the E...
Read more....
-
Shire Receives CHMP Positive Opinion for VPRIV
27 July 2010
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Hum...
Read more....
-
Cerezyme Emergency Treatment Program (CETP)
10 May 2010
Although the program had stopped in January 2010, it has been reinstated now due to continued shortage of Cerezyme supplies. The program is con...
Read more....
-
Product Supply Update
21 April 2010
Cerezyme Genzyme achieved its goal of building a small inventory buffer during the first quarter. The current shipping allocation of 50 percent of...
Read more....
-
Latest Cerezyme Update
17 February 2010
Latest Cerezyme Update - 17th February 2010: Due to several factors including to improve manufacturing quality systems and perform preventative mai...
Read more....
-
Recommendations for treating patients with Gaucher disease with emerging enzyme products
15 January 2010
A letter to the editor of the Blood Cells, Molecules and Diseases was published on the 18th December 2009 from Professor Timothy Cox, University of Ca...
Read more....
-
European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa
13 January 2010
Press Release Source: Protalix BioTherapeutics, Inc. On Wednesday January 13, 2010, 7:30 am CARMIEL, Israel, Jan. 13 /PRNewswire/ -- Protalix Bio...
Read more....
-
Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease
07 January 2010
Blood Cells, Molecules, and Diseases - 18th December 2009: Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendation...
Read more....